Kornimate/medical-research-clean huggingface dataset:
efficacy of myofascial trigger point pressure release on tinnitus patients

Conditions: Tinnitus; Myofascial Trigger Points

Summary: the objective of this study is to evaluate the efficacy of myofascial trigger (mtp) point deactivation for tinnitus control in a population with tinnitus and myofascial pain.

a double blind placebo control randomized clinical trial was made to verify the efficacy of the treatment by deactivation of mtp, after 10 sessions, in tinnitus patients by means of comparison with a placebo treatment in a control group. patients with tinnitus and frequent regional pain for at least 3 months in the head, neck and shoulder girdle were investigated in the tinnitus research group of university of são paulo medical school. all of them underwent an interview with the otolaryngologist ("physician researcher"), an audiologist evaluation ("blind researcher"), another blind researcher evaluation for tinnitus and pain and a physiotherapist evaluation and randomization. both blind researchers evaluated tinnitus and pain in the first, fifth and tenth session. the real treatment was made by a gradual and persistent digital pressure in each mtp previously diagnosed by the blind researcher (8 possible muscles) and some home orientations that included stretch, superficial heat in each treated muscle and watch the correct postures during daily activities and sleeping. in the control group physiotherapist researcher pressed in an adjacent non-tender muscle fibers of the same muscle that have mtp. no other complementary orientation was done.

Eligibility criteria:
inclusion criteria: 1. adult subjects of any gender, age and race with presence of uni or bilateral tinnitus for at least 3 months; 2. presence of pain complaint for at least 3 months in head, neck and shoulder girdle areas 3. presence of at least one myofascial trigger point (mtp) related with the patient's pain complaint (active mtp). exclusion criteria: 1. pain complaint involving three or more quadrants of the body, regardless of its cause 2. infiltration and/or specific treatment for deactivation of mtp in the last 6 months; 3. use of medications or other techniques to treat tinnitus, pain or muscle disorders during the previous last month; 4. impossibility of understanding the orientation and/or giving information during mtp evaluation (neurological or psychiatric diseases, bilateral severe or profound hearing loss, etc); 5. absence of tinnitus perception during evaluation; 6. pulsatile tinnitus or myoclonus (middle ear muscles or palatal myoclonus). 7. tinnitus due to certain etiologies that require other specific types of treatment, determined according to the medical evaluation.

Keywords: tinnitus myofascial trigger points myofascial pain syndrome controlled clinical trial
studying gene expression in samples from younger patients with neuroblastoma

Conditions: Neoplastic Syndrome; Neuroblastoma

Summary: rationale: studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer. purpose: this research trial studies gene expression in samples from younger patients with neuroblastoma.

objectives: * determine whether tβriii expression and tgf-β signaling decrease in advanced-stage neuroblastoma (nbl) and whether these changes are confined to the schwannian stroma. * determine whether stβriii levels and tgf-β signaling correlate with nbl stage, tumor stroma content, surface tβriii expression, and tgf-β signaling. outline: archived paraffin-embedded tissue and plasma samples are analyzed for tβriii expression, tgf-β signaling, and smad3 expression and phosphorylation by immunohistochemistry, enzyme-linked immunosorbent assay (elisa), and other assays. surface expression of tβriii in the neuroblastic and stromal tumor components are correlated with matched circulating levels of soluble tβriii. results are then correlated with each patient's outcome data, including stage.

Eligibility criteria:
disease characteristics: * tissue samples and matched plasma samples available from 1 of the following groups: * patients with low-stage (international neuroblastoma staging system \[inss\] stage 1 or 2) neuroblastoma (nbl) * patients with advanced-stage (inss stage 3 or 4) nbl * patients with stage 4s nbl * clinical and/or outcome data associated with the tissue and plasma samples including inss stage, age, mycn amplification status, chromosomal alterations, and 5-year survival, if known patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: disseminated neuroblastoma hereditary neuroblastoma localized resectable neuroblastoma localized unresectable neuroblastoma stage 4s neuroblastoma
a study of vx-445 combination therapy in cf subjects homozygous for f508del (f/f)

Conditions: Cystic Fibrosis

Summary: this study will evaluate the efficacy of vx-445 in triple combination (tc) with tezacaftor (tez) and ivacaftor (iva) in subjects with cystic fibrosis (cf) who are homozygous for the f508del mutation (f/f)


Eligibility criteria:
key inclusion criteria: * homozygous for the f508del mutation (f/f) * forced expiratory volume in 1 second (fev1) value ≥40% and ≤90% of predicted mean for age, sex, and height key exclusion criteria: * clinically significant cirrhosis with or without portal hypertension * lung infection with organisms associated with a more rapid decline in pulmonary status * solid organ or hematological transplantation other protocol defined inclusion/exclusion criteria may apply
role of functional neurosurgery in management of spasticity

Conditions: Functional Neurological Disorder

Summary: spasticity can result from a variety of causes in neural axis from which most common are cerebral palsy, strokes, cerebral haemorrhage, multiple sclerosis , traumatic brain injury and spinal cord injury and underlying mechanism is broadly due to decrease inhibition of the spinal network. clinical evaluation for spasticity involve series of clinical assessment , physical examination , and neurophysiological testing. quantitative evaluation of spasticity can be measured using modified ashworth scale which is the most widely used clinical spasticity scale and can be used for various clinical conditions causing spasticity

currently, the management of spasticity spans in a continuum between non-invasive and invasive intervention to modulate its effects and improve patients' quality of life and when spasticity becomes excessive and aggravates disability, functional neurosurgery can be a resource. neurosurgical procedures for management of spasticity are classified according to whether their effect is generalized or focal and whether they are reversible or irreversible. procedures include intrathecal baclofen pump , spinal cord stimulation and lesioning techniques peripheral nerves , dorsal roots , spinal cord or dorsal root entry zone

Eligibility criteria:
inclusion criteria: * patients with spasticity refractory to medical treatment (most commonly administered oral medications for managing spasticity are diazepam, dantrolene sodium, and baclofen) and physiotherapy exclusion criteria: * patients unfit for neurosurgical intervention
study on the chromatic perception of digital systems in aesthetic field

Conditions: Color Detection of Upper Central Incisors

Summary: the study under consideration aims to evaluate differences in chromatic perception among three distinct color acquisition methodologies. specifically, recruited patients will undergo testing with three different color detection systems, including two intraoral photography methodologies and one digital intra oral scanning. all procedures conducted are part of normal clinical practice.


Eligibility criteria:
inclusion criteria: * patients with good oral health * age over 18 years old * signing of an informed consent form according to the protocol exclusion criteria: * any type of restoration on the upper central and lateral incisors
balance training with tdcs for cai

Conditions: Ankle Injuries and Disorders

Summary: the purpose of this research study is to examine the efficacy of non-invasive brain stimulation in addition to balance exercise for chronic ankle instability (cai), a condition that develops following an initial ankle sprain, usually because of loose or unstable ankle joints.


Eligibility criteria:
inclusion criteria: * subjects should be neurologically sound * subjects should have abilities to maintain a single-leg stance at least for 10 seconds. * a history of ankle sprain * a history of ankle joint giving ways * current feelings of ankle joint instability exclusion criteria: * individuals with a clinically defined neurological disorder, with an increased risk of seizure for any reason, with a history of treatment with transcranial magnetic stimulation (tms), deep brain stimulation for any disorder will be excluded. * patients with cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed will be excluded. * a history of balance or vestibular disorder * a history of previous surgeries to the musculoskeletal structures in either limb of the lower extremity * a history of a fracture in either limb of the lower extremity requiring realignment * a history of acute injuries to the lower extremity joints in the previous 3 months, which impacted joint integrity and function (i.e., sprains, fractures) resulting in at least 1 interrupted day of desired physical activity * a history of herniated disc * poorly controlled headache * hypersensitivity to electrical or magnetic stimulation * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoner

Keywords: chronic ankle instability
identification the cause of silent cerebral infarction in healthy subjects (icons)

Conditions: Cerebral Infarction

Summary: we hypothesized that paradoxical embolism may be one of the main mechanisms of silent cerebral infarction (sci) located outside the perforating artery territory. in the present study, we evaluated the association between sci and paradoxical embolism detected by agitated saline transcranial doppler (tcd) monitoring in healthy subjects without history of stroke or transient ischemic attack (tia). we also compared the frequency and amount of paradoxical embolism between healthy subjects with sci and acute stroke patients with presumed cryptogenic embolism or conventional stroke mechanisms.


Eligibility criteria:
inclusion criteria: healthy subjects * subjects with age over 20 years * subjects who consecutively visited a health promotion center for a health screening examination that included routine laboratory test, cardiac work-ups (12-lead electrocardiography and/or echocardiography), and brain magnetic resonance image (mri) and mr angiography (mra) * subjects who showed silent brain infarction (sci) which was defined as a focal hyperintensity lesion 3 mm or large in diameter in the fluid-attenuation inversion recovery (flair) images without a history of a corresponding stroke or transient ischemic attack (tia) * subjects who performed agitated saline transcranial doppler (tcd) monitoring patients with acute stroke (both cryptogenic embolic stroke and conventional stroke mechanisms) * patients with age over 20 year * patients with focal neurologic deficits presented within 7 days of symptom onset * patients with acute ischemic lesions on diffusion-weighted image (dwi) * patients who performed agitated saline tcd monitoring exclusion criteria: healthy subjects * subjects with the presence of previous history of stroke or tia * subjects with the presence of dementia on history taking or mini-mental status examination * subjects with the presence of proximal source of embolism, including atrial fibrillation or significant (≥50%) stenosis on cervicocerebral artery on mra or carotid duplex * subjects who had sci restricted within perforator territory (basal ganglia or pons) suggesting that microangiopathy rather than embolism could be the main mechanism of sci * subjects in whom agitated saline tcd monitoring was not performed or those who had poor temporal windows patients with acute stroke (both cryptogenic embolic stroke and conventional stroke mechanisms) * patients in whom agitated saline tcd monitoring was not performed or those who had poor temporal windows

Keywords: stroke, ischemic patent foramen ovale magnetic resonance imaging paradoxical embolism transcranial doppler silent cerebral infarct
ingenol mebutate gel 0.05% in kidney transplant recipients with actinic keratoses

Conditions: Actinic Keratosis

Summary: the substance ingenol mebutate (im) is registered in switzerland and many countries worldwide for the treatment of actinic keratosis (ak). there is no data on the use of im in organ transplant recipients, a population highly affected by ak and skin cancer at large. the investigators want to study the use of im against ak in this high-risk group of patients and assess its safety. the investigators are hoping to prove that im is safe to use in ak of organ transplant recipients, allowing its use in the clinical routine treatement of ak also in this subset of patients with ak.

ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. if the 100 cm2 area is not cleared at day 57 (+/- 3 days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. in total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).

Eligibility criteria:
inclusion criteria: * male subjects 18 years of age or older * female subjects 18 years of age or older of non-child bearing potential defined by a serum follicle stimulating hormone (fsh) level ≥ 25.8 miu/ml or by a confirmed clinical history of sterility (e.g. hysterectomy) * renal transplantation performed two years or more before inclusion * stable renal transplant function as determined by physician * actinic keratosis, one or multiple, of the trunk and/or extremities, non-hypertrophic non-hyperkeratotic based on clinical judgment within an area of 100 cm2 total (several areas adding up to 100 cm2 permissible) * signed informed consent after oral and written explanation of the study protocol exclusion criteria: * contraindications on ethical grounds such as inability to give informed consent * women of child-bearing potential, women who are pregnant or breast feeding * other clinically significant concomitant disease (e.g. hepatic dysfunction, cardiovascular disease, etc) at the investigator's discretion * known or suspected non-compliance, drug or alcohol abuse * enrolment into a clinical trial within last 4 weeks * prior treatment with ingenol mebutate gel * prior local/topical treatments in the treatment area within 2 weeks of trial entry: * dermabrasion, chemical peeling, laser treatment, cryotherapy or surgery * imiquimod, diclofenac, 5-fluorouracil (5-fu), topical corticosteroids, topical retinoids, treatment with ultraviolet b (uvb) or photodynamic treatment (pdt)
functional magnetic resonance imaging - synthetic aperture magnetometry (fmri-sam) and alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fmri procedure, called fmri-sam. fmri-sam will be applied to 25 alzheimer's disease (ad) patients, 25 patients suffering from amnestic - mild cognitive impairment (mci) - a clinical picture which may be a prodromal form of ad - and 60 healthy controls. the first analysis of the data will search differences of brain activation profiles between the 3 groups. in the second step, the investigators will study the predictive value of fmri-sam to detect mci patients who will later convert to ad.


Eligibility criteria:
inclusion criteria: * alzheimer's disease of mild to moderate severity (25 patients) * amnestic mci patients (25 patients) * 55-75 year-old patients exclusion criteria: * any other cause of dementia for ad patients * any stroke * any disease with a negative vital prognosis
developing world study for rotateq™ (v260-015)(completed)

Conditions: Vomiting; Diarrhea; Fever

Summary: the purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.


Eligibility criteria:
inclusion criteria: * age 4 weeks through 12 weeks at dose 1 * parent able to understand study procedures and give consent exclusion criteria: * clinical evidence of active gastrointestinal disease * subjects who are currently or expected to participate in other studies of investigational products during the 6 weeks after receiving the last dose of rotateq™/placebo
comparison between manta and prostar closure devices

Conditions: Aortic Valve Stenosis

Summary: use of the closure device in patient with percutaneous transfemoral aortic valve replacement

the advent of endovascular, transcatheter aortic valve replacement (tavr), and mechanical circulatory support has offered new, minimally invasive therapeutic options that are rapidly becoming standard of care. these percutaneous transfemoral interventions require large-bore catheters and have created challenges for femoral arterial access management. current approaches include surgical cut-down with arterial puncture under direct vision, and suture-based "pre-closure." surgical cut-down is associated with longer procedural time, increased patient discomfort, deeper anesthesia, risk of wound complications including infection, and slower ambulation. the pre-closure technique overcomes many of the disadvantages of surgical cut-down but can be technically demanding, time consuming, and associated with a significant failure rate. recent randomized tavr trials have reported major vascular complications in 6% to 8% . furthermore, a study on the 2 suture-based closure techniques for management of tavr access reported a 20% vascular complication rate despite being used by experienced operators . currently, the majority of access site complications result from failed arteriotomy closure . the percutaneous manta vascular closure device (vcd) (essential medical inc., malvern, pennsylvania) is a novel collagen-based technology dedicated to closure of largebore arteriotomies . the manta vcd underwent prospective multicenter evaluation for conformitä europäenne (ce) mark approval in the first detailed report of outcomes achieved with a dedicated large-bore vascular closure device contrary to the aforementioned tavr procedures, mechanical circulatory support therapy can be extended up to several days on the intensive care ward. data on such delayed closure with is lacking. this registry is therefore aimed to document the initial experiences of delayed closure of a femoral large bore access with vascular closure devices in patients with an tavr device.

Eligibility criteria:
inclusion criteria: * patient scheduled for treatment with the tavr device 2. decision to use the manta or the prostar closure device on a clinical base by the treating physician 3. signed informed consent exclusion criteria: * male or female aged \< 18 2. pregnant and lactating females 3. patient has been committed to an institution by legal or regulatory order

Keywords: closure
exploring the therapeutic effect of telitacicept on lupus erythematosus complicated with thrombocytopenia

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia

this study is a single center, randomized, controlled trial to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus complicated with refractory thrombocytopenia.

Eligibility criteria:
inclusion criteria: 1. meets the 2012 acr revised standards and meets four or more diagnostic criteria for systemic lupus erythematosus; 2. refractory thrombocytopenia (defined as receiving at least one course of methylprednisolone pulse therapy or intravenous injection of high-dose immunoglobulin or high-dose glucocorticoid combined with two or more immunosuppressive drug failed and did not respond to any single drug); 3. sleena-sledai score is greater than or equal to 8 points. if anti ds-dna antibody is positive and/or low complement, sleena-sledai score is greater than or equal to 6 points, or plt count is\<10 \* 10 \^ 9/l or\<30 \* 10 \^ 9/l with bleeding tendency; 4. age greater than or equal to 18 years old and less than or equal to 65 years old; 5. have a stable sle treatment plan, and participants should receive standard treatment for at least 30 days before randomization; 6. positive antinuclear antibody or anti ds dna antibody; 7. sign informed documents. exclusion criteria: potential subjects who meet the inclusion criteria will be excluded if they meet any of the following criteria: 1. patients who are allergic to tamoxifen; 2. patients with severe active infection, history of tuberculosis, malignant tumor, hiv, hepatitis b, hepatitis c, important organs or hematopoietic stem cells/cells/bone marrow transplantation or kidney transplantation; 3. patients with severe active central nervous system lupus and severe active lupus nephritis 4. patients with diseases of liver, kidney, heart and other important organs, blood and endocrine system; 5. pregnant and lactating women; 6. have a pregnancy preparation plan in the past year; 7. those who have merged with other autoimmune diseases; 8. incomplete case data and missing persons.

Keywords: lupus erythematosus telitacicept thrombocytopenia
improving medication adherence through a transitional care pharmacy practice model

Conditions: Pulmonary Disease, Chronic Obstructive; Heart Failure

Summary: the purpose of this pilot study is to determine if medication adherence is improved by a transitional care pharmacy practice model designed to integrate hospital and community pharmacists in the care and education of patients with heart failure or copd who are discharged from a community hospital to home. the hospital and community pharmacists will collaborate with each other, the patient, and other practitioners including the primary care physician, nurse, and case manager to prevent and correct medication-related problems and attempt to improve patient outcomes especially during the error-prone transition from hospital to home.


Eligibility criteria:
inclusion criteria: * admitted to hospital with a primary or secondary diagnosis of heart failure or copd * anticipated eventual discharge to home * agreeable to participate in monthly counseling sessions (if randomized to intervention group) from a participating community pharmacist exclusion criteria: * presence of cognitive impairment or dementia that would significantly prevent effective patient education and counseling * non english-speaking * anticipated discharge to a long-term care or skilled nursing facility on a permanent basis * permanent long-term care facility residents * surgical patients * hospice patients * patients who die within 30 days of initial study hospitalization

Keywords: transition of care care transitions readmission medication adherence medication management medication reconciliation patient counseling pharmacist